Atazanavir/ritonavir has been generally well tolerated. However, rash has been reported in 1% to 6% of study participants. To date, there are few publications describing Atazanavir/ritonavir associated dermatological adverse events in any detail. We present the case of severe rash that occurred shortly after the initiation of Post Exposure Prophylaxis with atazanavir/ ritonavir in a health care professional. Clinicians should be aware of the safety profile of Post Exposure Prophylaxis drugs before administration.
A 33 year old HIV positive male patient rearing one domestic cattle presented with complaints of low back pain for 30 days, Fever with Chills and Rigors and non productive cough of 15 days duration. USG Abdomen showed Spleenomegaly with multiple small hypoechoic lesions and calcified foci. Diagnosis of Brucellosis was done based on the compatible clinical presentation and SAT titre of 1: 160. TB should be diagnosis of exclusion. HIV patients with PUO should be routinely screened for Brucellosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.